Form 4: Sagimet Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Director Timothy P. Walbert acquired stock options for 9,279 shares of Sagimet Biosciences Inc. on June 5, 2024.
Summary
- On June 5, 2024, Timothy P. Walbert, a director of Sagimet Biosciences Inc., acquired stock options for 9,279 shares.
- The exercise price of these options is $4.64.
- The options vest in twelve equal monthly installments starting June 5, 2024, contingent upon continued service.
- The expiration date for these options is June 4, 2034.
- Following the transaction, Walbert directly owns 9,279 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option acquisition by a director, neither particularly positive nor negative.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, transact in their company's stock, providing transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future prospects, potentially impacting shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Director acquired stock options. |
| 06/05/2024 | Vesting start date: Options vest in twelve equal monthly installments. |
| 06/04/2034 | Expiration date: Stock options expire. |
| 06/07/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.